Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Avidity Biosciences, Inc. (RNA) Long-Term Debt Issuances (2019)

Avidity Biosciences' Long-Term Debt Issuances history spans 1 years, with the latest figure at -$7000.0 for Q3 2019.

For Q3 2019, Long-Term Debt Issuances changed N/A year-over-year to -$7000.0; the TTM value through Dec 2020 reached -$7000.0, changed N/A, while the annual FY2019 figure was $19.5 million, 550.97% up from the prior year.
Long-Term Debt Issuances reached -$7000.0 in Q3 2019 per RNA's latest filing, down from $4.5 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $4.5 million in Q2 2019 to a low of -$7000.0 in Q3 2019.